Clinical study of Methylcantharidmide combined with transcatheter arterial chemo-embolization in the treatment of hepatocellular carcinoma
Objective:To investigate the clinical efficacy of Methylcantharidmide combined with transcatheter arterial chemoembolization(TACE)in treating hepatocellular carcinoma(HCC).Methods:A total of 60 HCC patients were included in the study,30 patients in the test group(combined with TACE)and 30 in the control group(TACE alone).After 12 months follow-up,glutamic-pyruvic transaminase(ALT),glutamic-oxalacetic transaminase(AST),total bilirubin(TBil),Child-Pugh(CP)score,ascites grade,quality of life(QOL),and tumor treatment response were evaluated.Results:After 12 months of treatment,ALT,AST,TBIL,CP score,ascites grade,and QOL score in the test group were statistically significant compared with the control group(P<0.05).There was no significant difference in the objective response rate between the two groups(P>0.05),while the disease control rate and survival rate of the test group were better than those of the control group(P<0.05).Conclusion:The treatment of Methylcantharidmide combined with TACE for HCC can not only reduce liver function damage,and improve the quality of life of patients,but also consolidate the treatment efficacy of TACE,improve the control rate of tumor and prolong the survival of patients,which is worthy of further clinical research and application.
NETL
NSTL
万方数据
维普
